Search | Page 9 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Flu Season Update

    ... be different. However, PNH patients who are receiving eculizumab may be less likely to have hemolysis after receiving a flu shot. ...

    Facts for Life last updated 02/01/2018 - 3:49pm.

  2. A Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients Who Have an Inadequate Response to Eculizumab

    ... (PNH) who have an inadequate response to eculizumab . Patients will be treated with RA101495 for 12 weeks. Note: ... by flow cytometry Inadequate response to eculizumab defined as having received eculizumab for at least 6 months plus ...

    Clinical Trial last updated 04/20/2017 - 11:14am.

  3. Pregnancy in Bone Marrow Failure Disease

    ... ability to become pregnant. For PNH, has the use of eculizumab in pregnancy been studied? There are cases of women who have been successfully treated with eculizumab. Recent information shows that with modern obstetric care, women ...

    Interview last updated 01/13/2017 - 9:28am.

  4. Resources to Help

    ... Assists patients who have been prescribed Solaris ( eculizumab ) by connecting them to alternate funding sources and by getting ...

    Topic section last updated 02/22/2018 - 9:51am.

  5. Chao-Yie Yang, MD, PhD

    ... . Current FDA-approved only treatment for PNH is eculizumab which is expensive, unable to eradicate PNH clone , not ... in PNH. Current only FDA-approved treatment for PNH is eculizumab which is expensive, unable to eradicate PNH clone , not ...

    Grant Recipient last updated 08/09/2016 - 1:02pm.

  6. Patrizia Ricci, PhD

    ... . Recently, the availability of the complement inhibitor eculizumab has dramatically improved the treatment of PNH. Nevertheless, about half of the patients treated with eculizumab shows a persistence of clinical signs of the disease. We have ...

    Grant Recipient last updated 09/14/2016 - 2:42pm.

  7. Antonio Maria Risitano, MD, PhD

    ... mechanism of hemolysis may emerge during eculizumab treatment; it can be designated as "C3-mediated extravascular ... possible explanations for the heterogeneity of response to eculizumab treatment, based on inherited factors. These studies were pivotal ...

    Bio last updated 10/20/2017 - 9:50am.

  8. Paroxysmal nocturnal hemoglobinuria following alemtuzumab immunosuppressive therapy for myelodysplastic syndrome and complicated by recurrent life-threatening thrombosis despite anticoagulation: successful intervention with eculizumab and fondaparinux

    Journal Title:  Leuk Res. Primary Author:  Cheng KL Author(s):  Cheng KL, Br...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. Special Precautions

    ... each case is different. PNH patients who are receiving eculizumab may be less likely to have hemolysis after receiving a flu ...

    Topic section last updated 09/08/2017 - 12:34pm.

  10. A Phase I Study to Assess the Safety APL-2 as an Add-On to Standard of Care in Subjects with PNH

    ... (PNH) who are still anemic after treatment with eculizumab (Soliris®). ... Diagnosed with PNH On treatment with eculizumab (Soliris®) for at least 3 months Hb < 10 g/dL at ...

    Clinical Trial last updated 07/19/2016 - 12:46pm.